A real‐world study of alemtuzumab in a cohort of Italian patientsCinzia Valeria Russo, Alessio Signori, Roberta Grasso et al.|European Journal of Neurology|2021Cited by 26
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapyElisabetta Signoriello, Alessio Signori, Giacomo Lus et al.|Multiple Sclerosis Journal|2021Cited by 19
The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control studyMarta Ponzano, Viola Baione, Irene Schiavetti et al.|Multiple Sclerosis and Related Disorders|2022Cited by 10